Oncology and Hematology: Archives

SUMMARY AND COMMENT

Flavopiridol for High-Risk CLL

• November 17, 2009
• Michael E. Williams, MD

Heavily pretreated patients with relapsed CLL experienced good responses to the cell cycle inhibitor flavopiridol.

• Reviewing:
• Lin TS et al., J Clin Oncol 2009 Oct 13

SUMMARY AND COMMENT

Predictors of Survival in DLBCL

• November 10, 2009
• Michael E. Williams, MD

A combination of techniques identified biomarkers that predicted survival in patients with diffuse large B-cell lymphoma.

• Reviewing:
• Copie-Bergman C et al., J Clin Oncol 2009 Sep 28

SUMMARY AND COMMENT

Breast Cancer and BRCA Status in Young Women of Diverse Racial Groups

• November 10, 2009
• William J. Gradishar, MD

Frequencies of deletion mutations in BRCA1/2 genes were similar across racial groups.

• Reviewing:
• Haffty BG et al., Ann Oncol 2009 Oct; 20:1653

SUMMARY AND COMMENT

Octreotide Treatment for Neuroendocrine Tumors

• November 10, 2009
• David H. Ilson, MD, PhD

In treatment-naive patients, octreotide substantially lengthened time to tumor progression.

• Reviewing:
• Rinke A et al., J Clin Oncol 2009 Oct 1; 27:4656

SUMMARY AND COMMENT

Open vs. Minimally Invasive Radical Prostatectomy

• November 10, 2009
• Robert Dreicer, MD, MS, FACP

Each surgical approach conferred certain advantages, but conclusions about outcomes are limited by data collection methodology.

• Reviewing:
• Hu JC et al., JAMA 2009 Oct 14; 302:1557

SUMMARY AND COMMENT

A Novel Erythropoietin Receptor Agonist for Red Cell Aplasia

• November 4, 2009
• David Green, MD, PhD

Hemoglobin levels improved after treatment in patients who had antierythropoietin antibodies.

• Reviewing:
• Macdougall IC et al., N Engl J Med 2009 Nov 5; 361:1848

SUMMARY AND COMMENT

Omitting Radiation for Patients with DCIS

• November 3, 2009
• Henry Mark Kuerer, MD, PhD, FACS

Local tumor excision alone yielded acceptably low rates of local recurrence in patients with low- and intermediate-grade DCIS.

• Reviewing:
• Hughes LL et al., J Clin Oncol 2009 Oct 13

SUMMARY AND COMMENT

MicroRNA Expression in Hepatocellular Cancer

• November 3, 2009
• David H. Ilson, MD, PhD

Low expression of miR-26 seemed to affect survival and predict response to interferon.

• Reviewing:
• Ji J et al., N Engl J Med 2009 Oct 8; 361:1437

SUMMARY AND COMMENT

CYP2D6 Polymorphisms and Response to Tamoxifen

• October 27, 2009
• Virginia Kaklamani, MD, DSc

Breast cancer patients with genotypes corresponding to normal CYP2D6 enzyme activity achieved better outcomes than those with diminished or no activity.

• Reviewing:
• Schroth W et al., JAMA 2009 Oct 7; 302:1429

SUMMARY AND COMMENT

Preventing Oral Mucositis in Cancer Treatment

• October 27, 2009
• Barbara A. Murphy, MD

Recombinant human intestinal trefoil factor produced encouraging results.

• Reviewing:
• Peterson DE et al., J Clin Oncol 2009 Sep 10; 27:4333